Freestone Grove Partners LP acquired a new stake in Adaptive Biotechnologies Corp. The institutional investor purchased 881,688 shares. This transaction is valued at approximately $18.9 million. The acquisition gives the fund a 0.55% ownership stake in the company.
The stock maintains strong momentum with significant returns over the last one, three, and twelve months. Analysts attribute the positive market sentiment to improving profitability within the Minimal Residual Disease (MRD) segment. The company also reported a notable reduction in cash burn.